Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer

Press Launch

current: Jun 26, 2020 09:00 CEST

Philogen S.p.A., a privately-owned biotechnology company, is delighted to announce that the Swiss national competent authority Swissmedic issued the authorization to operate a scientific section II review in people with locally advanced, not metastatic nonmelanoma skin cancer. A favorable impression about the review has now also been obtained by EKOS (Ethics Committee of Jap Switzerland).

Patients enrolled in the scientific review will be dealt with with intralesional injections of NidlegyTM. NidlegyTM, the mixture of the two active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF), has already proven promising effects in the intralesional neoadjuvant cure of people with resectable Phase III melanoma in two section III scientific trials. The tough responses, the superb basic safety profile and the favorable beauty final result of injected melanoma lesions have reinforced the investigation of efficacy and basic safety of NidlegyTM in injectable, locally advanced and not metastatic lesions of basal cell carcinoma or cutaneous squamous cell carcinoma.

“We are delighted to commence the scientific section II review in Switzerland and to examine the opportunity of NidlegyTM in people with locally advanced, not metastatic nonmelanoma skin cancer,” commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.

About the Philogen group

Philogen is a Swiss-Italian scientific-stage company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s approach is to supply bioactive brokers, for illustration, cytokines or medication, to the internet site of sickness working with antibodies and other ligands that precisely and proficiently concentrate on stromal antigens. This technological innovation has created a solid proprietary pipeline of scientific-stage products and preclinical compounds in an array of sickness indications. Philogen is headquartered in Siena, Italy, and has research actions at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with many important pharmaceutical providers. For more info, make sure you visit and

For more info make sure you call:

Dr. Christian Lizak

+41 () forty three 544 88 00

[email protected]

Resource: Philogen S.p.A.